NCT00367237 - A Randomized, Multicenter, International, Open-label Study of Infliximab Plus Methotrexate Versus Methotrexate (MTX) Alone for the Treatment of MTX naïve Subjects With Active Psoriatic Arthritis - The YODA Project (original) (raw)
A Randomized, Multicenter, International, Open-label Study of Infliximab Plus Methotrexate Versus Methotrexate (MTX) Alone for the Treatment of MTX naïve Subjects With Active Psoriatic Arthritis
You are not logged in.
Please login to continue selecting trials.
Trial Information
Generic NameInfliximabProduct NameREMICADE®Therapeutic AreaImmune System DiseasesEnrollment115% Female45.5%% WhiteN/A
Product ClassAntirheumatic Agents - Biologic Response ModifiersSponsor Protocol NumberP04422Data PartnerJohnson & JohnsonCondition StudiedArthritis, PsoriaticMean/Median Age (Years)41.2
Supporting Documentation
- Collected Datasets Available
- Protocol with Amendments Available
- Clinical Study Report Available